Logo image of AUGX

AUGMEDIX INC (AUGX) Stock Fundamental Analysis

NASDAQ:AUGX - Nasdaq - US05105P1075 - Common Stock - Currency: USD

2.35  0 (0%)

After market: 2.35 0 (0%)

Fundamental Rating

2

Taking everything into account, AUGX scores 2 out of 10 in our fundamental rating. AUGX was compared to 35 industry peers in the Health Care Technology industry. AUGX may be in some trouble as it scores bad on both profitability and health. AUGX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AUGX has reported negative net income.
AUGX had a negative operating cash flow in the past year.
AUGX had negative earnings in each of the past 5 years.
In the past 5 years AUGX always reported negative operating cash flow.
AUGX Yearly Net Income VS EBIT VS OCF VS FCFAUGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -44.44%, AUGX is doing worse than 65.79% of the companies in the same industry.
AUGX has a worse Return On Equity (-227.72%) than 81.58% of its industry peers.
Industry RankSector Rank
ROA -44.44%
ROE -227.72%
ROIC N/A
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AUGX Yearly ROA, ROE, ROICAUGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

The Gross Margin of AUGX (48.21%) is worse than 60.53% of its industry peers.
AUGX's Gross Margin has improved in the last couple of years.
AUGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
AUGX Yearly Profit, Operating, Gross MarginsAUGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

More info and screens

2

2. Health

2.1 Basic Checks

AUGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AUGX has more shares outstanding
The number of shares outstanding for AUGX has been increased compared to 5 years ago.
Compared to 1 year ago, AUGX has an improved debt to assets ratio.
AUGX Yearly Shares OutstandingAUGX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AUGX Yearly Total Debt VS Total AssetsAUGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -2.71, we must say that AUGX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.71, AUGX is not doing good in the industry: 65.79% of the companies in the same industry are doing better.
AUGX has a Debt/Equity ratio of 1.48. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of AUGX (1.48) is worse than 84.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Altman-Z -2.71
ROIC/WACCN/A
WACC9%
AUGX Yearly LT Debt VS Equity VS FCFAUGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

AUGX has a Current Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.66, AUGX is in line with its industry, outperforming 47.37% of the companies in the same industry.
AUGX has a Quick Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.66, AUGX is in line with its industry, outperforming 47.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
AUGX Yearly Current Assets VS Current LiabilitesAUGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.66% over the past year.
The Revenue has grown by 39.34% in the past year. This is a very strong growth!
Measured over the past years, AUGX shows a very strong growth in Revenue. The Revenue has been growing by 32.90% on average per year.
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%

3.2 Future

Based on estimates for the next years, AUGX will show a small growth in Earnings Per Share. The EPS will grow by 6.46% on average per year.
The Revenue is expected to grow by 11.58% on average over the next years. This is quite good.
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AUGX Yearly Revenue VS EstimatesAUGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
AUGX Yearly EPS VS EstimatesAUGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AUGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AUGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AUGX Price Earnings VS Forward Price EarningsAUGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AUGX Per share dataAUGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.76%
EPS Next 3Y6.46%

More info and screens

0

5. Dividend

5.1 Amount

AUGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AUGMEDIX INC

NASDAQ:AUGX (10/1/2024, 8:00:01 PM)

After market: 2.35 0 (0%)

2.35

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-12 2024-08-12/amc
Earnings (Next)11-04 2024-11-04/bmo
Inst Owners72.68%
Inst Owner Change0%
Ins Owners11.72%
Ins Owner Change0%
Market Cap116.16M
Analysts80
Price Target3.6 (53.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.31%
Min EPS beat(2)4.41%
Max EPS beat(2)12.2%
EPS beat(4)4
Avg EPS beat(4)11.24%
Min EPS beat(4)4.41%
Max EPS beat(4)16.56%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-1.76%
Max Revenue beat(2)-1.2%
Revenue beat(4)1
Avg Revenue beat(4)-0.56%
Min Revenue beat(4)-1.76%
Max Revenue beat(4)0.98%
Revenue beat(8)4
Avg Revenue beat(8)0.08%
Revenue beat(12)5
Avg Revenue beat(12)-0.26%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.74%
EPS NY rev (1m)0%
EPS NY rev (3m)1.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.25
P/FCF N/A
P/OCF N/A
P/B 11.09
P/tB 11.09
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS1.04
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.44%
ROE -227.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.21%
FCFM N/A
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
F-Score5
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 180.82%
Cap/Sales 4.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -2.71
F-Score5
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)178.38%
Cap/Depr(5y)139.24%
Cap/Sales(3y)4.74%
Cap/Sales(5y)4.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A
EBIT growth 1Y-14.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.28%
EBIT Next 3Y9.53%
EBIT Next 5YN/A
FCF growth 1Y12.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.91%
OCF growth 3YN/A
OCF growth 5YN/A